Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Univ. of South China NAMPT compound Q24: sourced facts only. name: "Among them, Q24 exhibited the strongest activity, showing nanomolar inhibition of NAMPT and subnanomolar antiproliferative effects against HGC-27 cells." [PMID:41722430]; target: "Among them, Q24 exhibited the strongest activity, showing nanomolar inhibition of NAMPT and subnanomolar antiproliferative effects against HGC-27 cells." [PMID:41722430]; developer: "School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China." [PMID:41722430]; modality: "we designed and synthesized a series of 29 small-molecule NAMPT inhibitors derived from lead compound 9a" [PMID:41722430]; stage: "In xenograft models, Q24 significantly inhibited tumor growth, achieving a tumor growth inhibition rate of 68.9% without notable histopathological abnormalities." [PMID:41722430]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Univ. of South China NAMPT compound Q24.